uracil has been researched along with Neutropenia in 31 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer." | 9.34 | Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. ( Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A, 2020) |
| "Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)." | 9.20 | Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015) |
| "To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)." | 9.19 | Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014) |
| "This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer." | 9.09 | UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "The aim of this report was to evaluate the onset of grade≥3 neutropenia during the first-cycle in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil and its relationship with clinical parameters of interest, such as overall survival (OS)." | 7.91 | The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. ( Bonetti, A; Giuliani, J, 2019) |
| "The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients." | 7.88 | Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018) |
| "Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 7.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
| "The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer." | 5.34 | Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials. ( Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A, 2020) |
| "Oral tegafur/uracil and leucovorin (UFT/LV) therapy is effective and safe for elderly patients with advanced or metastatic colorectal cancer (CRC)." | 5.20 | Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hasegawa, J; Hata, T; Ikeda, M; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ota, H; Sekimoto, M; Takemasa, I; Tamagawa, H; Tsujie, M; Yamamoto, H, 2015) |
| "To investigate the efficacy of gemcitabine plus uracil-tegafur (UFT) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC)." | 5.19 | Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. ( Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY, 2014) |
| "This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer." | 5.09 | UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. ( Gregory, RK; Johnston, SR; Miles, D; Smith, IE, 2000) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102)." | 4.31 | Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias. ( Fujii, H; Hirose, C; Hishida, S; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Suzuki, A; Tajima, JY; Takahashi, T; Watanabe, D, 2023) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "The aim of this report was to evaluate the onset of grade≥3 neutropenia during the first-cycle in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil and its relationship with clinical parameters of interest, such as overall survival (OS)." | 3.91 | The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. ( Bonetti, A; Giuliani, J, 2019) |
| "The RECOURSE trial showed clinical efficacy for trifluridine/tipiracil for refractory metastatic colorectal cancer patients." | 3.88 | Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. ( Baars, A; Beerepoot, LV; Boot, H; Creemers, GJ; de Groot, JW; Hamberg, P; Jansen, RL; Kapiteijn, E; Koopman, M; Kwakman, JJM; Los, M; Opdam, FL; Punt, CJA; Schut, H; Sommeijer, DW; van Meerten, E; van Rooijen, JM; Vestjens, JH; Vink, G; Vulink, AJE, 2018) |
| "Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)." | 3.88 | Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018) |
| "The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated." | 3.85 | Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2017) |
| "Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral UFT (tegafur and uracil) and oral leucovorin (the MUL regimen)." | 3.69 | Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. ( Ayala, F; Casado, A; Diaz-Rubio, E; López-Martin, JA; Martin, M; Nieto, Y; Rodriguez-Lescure, A, 1997) |
| " Major adverse events were neutropenia, leukopenia, anemia, and nausea." | 2.82 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016) |
| "The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy." | 2.79 | Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014) |
| "Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)." | 2.74 | Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. ( Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009) |
| " Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps." | 2.71 | [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. ( Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| " The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump." | 2.69 | A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. ( Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000) |
| "Neutropenia is the most common adverse event and an important factor impacting chemotherapy continuation." | 1.48 | Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. ( Aisu, N; Daibo, K; Hasegawa, S; Kajitani, R; Kiyomi, F; Komono, A; Matsumoto, Y; Munechika, T; Sakamoto, R; Yoshida, Y, 2018) |
| " Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95." | 1.43 | Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.45) | 18.2507 |
| 2000's | 8 (25.81) | 29.6817 |
| 2010's | 15 (48.39) | 24.3611 |
| 2020's | 6 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Van Cutsem, E | 4 |
| Hochster, H | 3 |
| Shitara, K | 3 |
| Mayer, R | 3 |
| Ohtsu, A | 5 |
| Falcone, A | 4 |
| Yoshino, T | 5 |
| Doi, T | 4 |
| Ilson, DH | 3 |
| Arkenau, HT | 3 |
| George, B | 3 |
| Benhadji, KA | 3 |
| Makris, L | 4 |
| Tabernero, J | 3 |
| Shiroyama, M | 1 |
| Fukuoka, S | 1 |
| Masuishi, T | 2 |
| Takashima, A | 1 |
| Kumekawa, Y | 1 |
| Kajiwara, T | 1 |
| Yamazaki, K | 3 |
| Shimada, Y | 2 |
| Esaki, T | 2 |
| Makiyama, A | 2 |
| Moriwaki, T | 2 |
| Watanabe, D | 1 |
| Fujii, H | 1 |
| Ohata, K | 1 |
| Iihara, H | 1 |
| Kobayashi, R | 1 |
| Hirose, C | 1 |
| Hishida, S | 1 |
| Matsuoka, S | 1 |
| Tajima, JY | 1 |
| Kiyama, S | 1 |
| Takahashi, T | 1 |
| Suzuki, A | 1 |
| Matsuhashi, N | 1 |
| Kasi, PM | 1 |
| Grothey, A | 1 |
| Cleary, JM | 1 |
| Mayer, RJ | 1 |
| Shinozaki, E | 1 |
| Nishina, T | 1 |
| Garcia-Carbonero, R | 1 |
| Komatsu, Y | 1 |
| Baba, H | 1 |
| Argilés, G | 1 |
| Tsuji, A | 1 |
| Sobrero, A | 1 |
| Yamaguchi, K | 1 |
| Peeters, M | 1 |
| Muro, K | 2 |
| Zaniboni, A | 1 |
| Sugimoto, N | 1 |
| Tsuji, Y | 1 |
| Hochster, HS | 1 |
| Tran, B | 1 |
| Hamada, C | 1 |
| Tanase, T | 1 |
| Benedetti, F | 1 |
| Yamashita, F | 1 |
| Lenz, HJ | 1 |
| Tsuchiya, T | 1 |
| Kamohara, R | 1 |
| Muraoka, M | 1 |
| Nagayasu, T | 1 |
| Saeki, S | 1 |
| Takenoyama, M | 1 |
| Suzuki, M | 2 |
| Inada, K | 1 |
| Tokunaga, S | 1 |
| Hayashi, T | 1 |
| Urabe, S | 1 |
| Koga, T | 1 |
| Akamine, S | 1 |
| Sugio, K | 1 |
| Kwakman, JJM | 1 |
| Vink, G | 1 |
| Vestjens, JH | 1 |
| Beerepoot, LV | 1 |
| de Groot, JW | 1 |
| Jansen, RL | 1 |
| Opdam, FL | 1 |
| Boot, H | 1 |
| Creemers, GJ | 1 |
| van Rooijen, JM | 1 |
| Los, M | 1 |
| Vulink, AJE | 1 |
| Schut, H | 1 |
| van Meerten, E | 1 |
| Baars, A | 1 |
| Hamberg, P | 1 |
| Kapiteijn, E | 1 |
| Sommeijer, DW | 1 |
| Punt, CJA | 1 |
| Koopman, M | 1 |
| Kimura, M | 4 |
| Usami, E | 4 |
| Iwai, M | 3 |
| Teramachi, H | 3 |
| Yoshimura, T | 4 |
| Yasue, F | 1 |
| Kawachi, S | 1 |
| Mitsuoka, M | 1 |
| Ikeda, Y | 1 |
| Yoshida, Y | 1 |
| Sakamoto, R | 1 |
| Kajitani, R | 1 |
| Munechika, T | 1 |
| Matsumoto, Y | 1 |
| Komono, A | 1 |
| Aisu, N | 1 |
| Daibo, K | 1 |
| Kiyomi, F | 1 |
| Hasegawa, S | 1 |
| Kashiwabara, K | 1 |
| Semba, H | 1 |
| Fujii, S | 1 |
| Tsumura, S | 1 |
| Giuliani, J | 1 |
| Bonetti, A | 1 |
| Sunaga, T | 1 |
| Suzuki, S | 1 |
| Kogo, M | 1 |
| Kurihara, T | 1 |
| Kaji, S | 1 |
| Koike, N | 1 |
| Harada, N | 1 |
| Kiuchi, Y | 1 |
| Lee, KW | 1 |
| Kim, YJ | 1 |
| Lee, KH | 1 |
| Han, SW | 1 |
| Kim, TY | 2 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Bang, YJ | 1 |
| Choi, IS | 1 |
| Kim, JH | 1 |
| Tsuburaya, A | 1 |
| Yoshida, K | 1 |
| Kobayashi, M | 1 |
| Yoshino, S | 1 |
| Takahashi, M | 1 |
| Takiguchi, N | 1 |
| Tanabe, K | 1 |
| Takahashi, N | 1 |
| Imamura, H | 1 |
| Tatsumoto, N | 1 |
| Hara, A | 1 |
| Nishikawa, K | 1 |
| Fukushima, R | 1 |
| Nozaki, I | 1 |
| Kojima, H | 1 |
| Miyashita, Y | 1 |
| Oba, K | 1 |
| Buyse, M | 1 |
| Morita, S | 1 |
| Sakamoto, J | 1 |
| Mizushima, T | 1 |
| Tamagawa, H | 1 |
| Matsuda, C | 1 |
| Murata, K | 1 |
| Fukunaga, M | 1 |
| Ota, H | 1 |
| Hasegawa, J | 1 |
| Tsujie, M | 1 |
| Fukuzaki, T | 1 |
| Hata, T | 1 |
| Takemasa, I | 1 |
| Ikeda, M | 1 |
| Yamamoto, H | 1 |
| Sekimoto, M | 1 |
| Nezu, R | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Kojima, T | 1 |
| Bando, H | 1 |
| Yamazaki, T | 1 |
| Naito, Y | 1 |
| Mukai, H | 1 |
| Fuse, N | 1 |
| Goto, K | 1 |
| Ito, Y | 1 |
| Go, M | 1 |
| Ito, D | 1 |
| Asano, H | 1 |
| Hamauchi, S | 1 |
| Kito, Y | 1 |
| Komori, A | 1 |
| Tsushima, T | 1 |
| Narita, Y | 1 |
| Todaka, A | 1 |
| Ishihara, M | 1 |
| Yokota, T | 1 |
| Tanaka, T | 1 |
| Machida, N | 1 |
| Kadowaki, S | 1 |
| Fukutomi, A | 1 |
| Ura, T | 1 |
| Onozawa, Y | 1 |
| Ando, M | 1 |
| Tajika, M | 1 |
| Yasui, H | 1 |
| Mori, K | 1 |
| Taniguchi, H | 1 |
| Surmont, V | 1 |
| Aerts, JG | 1 |
| Pouw, E | 1 |
| Tan, KY | 1 |
| Vernhout, R | 1 |
| Gras, J | 1 |
| Salomé, J | 1 |
| Pronk, T | 1 |
| Schmitz, PI | 1 |
| Hoogsteden, H | 1 |
| van Klaveren, RJ | 1 |
| Bin, Q | 1 |
| Li, J | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Rothenberg, ML | 1 |
| Benedetti, JK | 1 |
| Macdonald, JS | 1 |
| Seay, TE | 1 |
| Neubauer, MA | 1 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Giguere, JK | 1 |
| Pruitt, BT | 1 |
| Abbruzzese, JL | 1 |
| Nakamori, S | 1 |
| Tujie, M | 1 |
| Takahashi, Y | 1 |
| Maruhashi, S | 1 |
| Miyamoto, A | 1 |
| Nagano, H | 1 |
| Dono, K | 1 |
| Umeshita, K | 1 |
| Sakon, M | 1 |
| Monden, M | 1 |
| Ishida, H | 1 |
| Akita, H | 1 |
| Watanabe, Y | 1 |
| Nakaguchi, K | 1 |
| Kabuto, T | 1 |
| Iwamoto, S | 1 |
| Yoshioka, K | 1 |
| Rivera, F | 1 |
| Vega-Villegas, ME | 1 |
| López-Brea, MF | 1 |
| García-Castaño, A | 1 |
| de Juan, A | 1 |
| Ramos, FJ | 1 |
| Collado, A | 1 |
| Galdós, P | 1 |
| Rubio, A | 1 |
| del Valle, A | 1 |
| Rama, J | 1 |
| Mayorga, M | 1 |
| Sanz-Ortiz, J | 1 |
| Martin, M | 1 |
| Casado, A | 1 |
| López-Martin, JA | 1 |
| Rodriguez-Lescure, A | 1 |
| Nieto, Y | 1 |
| Ayala, F | 1 |
| Diaz-Rubio, E | 2 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Childs, HA | 1 |
| Spencer, SA | 1 |
| Raben, D | 1 |
| Bonner, JA | 1 |
| Newsome, J | 1 |
| Robert, F | 1 |
| Gregory, RK | 1 |
| Johnston, SR | 1 |
| Smith, IE | 1 |
| Miles, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies[NCT01607957] | Phase 3 | 800 participants (Actual) | Interventional | 2012-06-17 | Completed | ||
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
| Intervention | months (Median) |
|---|---|
| TAS-102 | 7.1 |
| Placebo | 5.3 |
Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated. (NCT01607957)
Timeframe: Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)
| Intervention | months (Median) |
|---|---|
| TAS-102 | 2.0 |
| Placebo | 1.7 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs. (NCT01607957)
Timeframe: From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any adverse event (AE) | Any treatment-related AE | Any ≥Grade 3 AE | Any treatment-related ≥Grade 3 AE | Any serious AE (SAE) | Any AE resulting in discontinuation | Any AE with outcome of death | |
| Placebo | 93.2 | 54.7 | 51.7 | 9.8 | 33.6 | 13.6 | 11.3 |
| TAS-102 | 98.3 | 85.7 | 69.4 | 49.0 | 29.6 | 10.3 | 3.2 |
1 review available for uracil and Neutropenia
| Article | Year |
|---|---|
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
14 trials available for uracil and Neutropenia
| Article | Year |
|---|---|
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; H | 2022 |
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Japan; Neutropenia; Pyrrolidines; Thymine; Trifluri | 2020 |
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Non-Small-Cell Lung; | 2020 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deo | 2014 |
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2015 |
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross- | 2016 |
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2009 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; D | 2004 |
Long term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in non-resectable locally advanced (stage IV-B) squamous
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Car | 2007 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2000 |
UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2000 |
16 other studies available for uracil and Neutropenia
| Article | Year |
|---|---|
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2023 |
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine; U | 2020 |
Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2017 |
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans; | 2018 |
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease-Free Survival; | 2018 |
Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2018 |
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
The Onset of Grade ≥3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Female; Hum | 2019 |
The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2014 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; | 2016 |
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Drug Combinations; Fema | 2017 |
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop | 2006 |
[24 hour infusion of CPT-11/oral UFT/LV].
Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2006 |
Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support.
Topics: Adult; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea | 1997 |